Global orthopedic sales totaled $59 billion in 2023, an increase of 6.5% compared to 2022. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
Global orthopedic sales totaled $59 billion in 2023, an increase of 6.5% compared to 2022. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
Stay up to date on the orthopedic market’s 2Q performance in 2024 as we update this post with company sales data and industry developments.
The U.S. remains the world’s largest orthopedic market by revenue, but companies see significant opportunities for international growth.
Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management.
The company grew in the high single digits in 2024 as it made significant progress integrating its Lima acquisition.
The company grew nearly 27% in 2024 as its technology and procedural approach continued to compel surgeon adoption in the spine market.
The company grew in the high single digits in 2024 and made moves to prioritize its most profitable growth opportunities in 2025.
The company’s 12-Point Plan is producing results, but China will remain a major drag on sales and profitability in 2025.
Eventum provides the QuadSense device that helps surgeons precisely cut and place the kneecap in total knee replacements.
Proceeds will be used to increase the company’s market penetration and develop further clinical data in support of the EnFix family of allograft products.
Funds will support commercialization of the InSet Total Shoulder and Reverse systems and new product development.
Over the last four years, spine M&A volume declined significantly while digital and orthobiologic assets saw increased activity.
Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management.
The company grew in the high single digits in 2024 as it made significant progress integrating its Lima acquisition.
The company grew nearly 27% in 2024 as its technology and procedural approach continued to compel surgeon adoption in the spine market.
The company grew in the high single digits in 2024 and made moves to prioritize its most profitable growth opportunities in 2025.
The company’s 12-Point Plan is producing results, but China will remain a major drag on sales and profitability in 2025.
Enabling technology is disrupting the competitive dynamics of the biggest orthopedic markets like joint replacement and spine.
Login
Register for a free account
As a guest member you get access to more articles and videos every month.